# A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

> **NCT07006792** · PHASE4 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 200 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Lebrikizumab

## Key facts

- **NCT ID:** NCT07006792
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2026-04
- **Final completion:** 2026-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07006792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07006792, "A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07006792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*